CEO Buell’s Latest Buy Signals Confidence in MINK Therapeutics’ iNKT Cell Therapy Breakthrough
CEO Jennifer Buell’s fresh 23k‑share buy shows strong confidence in MINK Therapeutics’ iNKT cell therapy pipeline amid a tough biotech market, signaling potential upside for investors.
4 minutes to read